Journal
EBIOMEDICINE
Volume 81, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ebiom.2022.104095
Keywords
Remdesivir; GS-441524; Microdialysis; Blood-placental barrier; Pharmacokinetics
Funding
- Ministry of Science and Technology of Taiwan [MOST 110-2918-I-239-001, MOST 110-2113-M-A49A-503, MOST 109-2113-M-010-007]
- College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
Ask authors/readers for more resources
This study demonstrates through experiments that remdesivir and its main metabolite, GS-441524, can cross the placenta, but remdesivir itself cannot directly enter the fetus. This finding suggests that caution should be taken when using remdesivir to treat COVID-19 during pregnancy.
Background Remdesivir was the first prodrug approved to treat coronavirus disease 2019 (COVID-19) and has the potential to be used during pregnancy. However, it is not known whether remdesivir and its main metabolite, GS 441524 have the potential to cross the blood-placental barrier. We hypothesize that remdesivir and predominant metabolite GS-441524may cross the blood-placental barrier to reach the embryo tissues. Methods To test this hypothesis, ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) coupled with multisite microdialysis was used to monitor the levels of remdesivir and the nucleoside analogue GS-441524 in the maternal blood, fetus, placenta, and amniotic fluid of pregnant Sprague-Dawley rats. The transplacental transfer was evaluated using the pharmacokinetic parameters of AUC and mother-to-fetus transfer ratio (AUCfetus/AUCmother). Findings Our in-vivo results show that remdesivir is rapidly biotransformed into GS-441524 in the maternal blood, which then readily crossed the placenta with a mother-to-fetus transfer ratio of 0.51 +/- 0.18. The C-max and AUC(last) values of GS-441524 followed the order: maternal blood > amniotic fluid > fetus > placenta in rats. Interpretation While remdesivir does not directly cross into the fetus, however, its main metabolite, GS-441524 readily crosses the placenta and can reside there for at least 4 hours as shown in the pregnant Sprague-Dawley rat model. These findings suggest that careful consideration should be taken for the use of remdesivir in the treatment of COVID-19 in pregnancy. eBioMedicine 104095 Published https://doi.org/10.1016/j. ebiom.2022.104095 Copyright (c) 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available